PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24621440-0	2015	Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein.	cabozantinib	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	107-121	
24621440-2	2015	This study assessed the mechanistic effect of cabozantinib on the reversal of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR).	cabozantinib	46-58	ATP binding cassette subfamily B member 1	Homo sapiens	78-92	
24621440-2	2015	This study assessed the mechanistic effect of cabozantinib on the reversal of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR).	cabozantinib	46-58	ATP binding cassette subfamily B member 1	Homo sapiens	94-98	
24621440-8	2015	The binding mechanism of cabozantinib to P-gp at the molecular level was evaluated using docking analysis.	cabozantinib	25-37	ATP binding cassette subfamily B member 1	Homo sapiens	41-45	
24621440-9	2015	RESULTS: Cabozantinib enhanced the cytotoxicity of P-gp substrate drugs in HepG2/adr and HEK293-MDR1 cells but had no effect on non-P-gp substrates.	cabozantinib	9-21	ATP binding cassette subfamily B member 1	Homo sapiens	51-55	
24621440-10	2015	In addition, cabozantinib increased the accumulation of P-gp substrates in HepG2/adr cells but had no effect in HepG2 cells.	cabozantinib	13-25	ATP binding cassette subfamily B member 1	Homo sapiens	56-60	
24621440-11	2015	Furthermore, cabozantinib did not alter the expression of P-gp mRNA or protein but did stimulate the activity of P-gp ATPase.	cabozantinib	13-25	ATP binding cassette subfamily B member 1	Homo sapiens	113-117	
24621440-12	2015	The docking study indicated that cabozantinib and verapamil may partially share a binding site on P-gp.	cabozantinib	33-45	ATP binding cassette subfamily B member 1	Homo sapiens	98-102	
24621440-14	2015	Significantly, cabozantinib increased the inhibitory efficacy of doxorubicin in P-gp-overexpressing HepG2/adr cell xenografts in nude mice.	cabozantinib	15-27	ATP binding cassette subfamily B member 1	Homo sapiens	80-84	
24621440-15	2015	CONCLUSION: Cabozantinib reverses P-gp-mediated MDR by directly inhibiting the efflux function of P-gp, indicating that cabozantinib may help to reverse P-gp-mediated MDR in HCC and other cancer chemotherapy.	cabozantinib	12-24	ATP binding cassette subfamily B member 1	Homo sapiens	34-38	
24621440-15	2015	CONCLUSION: Cabozantinib reverses P-gp-mediated MDR by directly inhibiting the efflux function of P-gp, indicating that cabozantinib may help to reverse P-gp-mediated MDR in HCC and other cancer chemotherapy.	cabozantinib	12-24	ATP binding cassette subfamily B member 1	Homo sapiens	98-102	
24621440-15	2015	CONCLUSION: Cabozantinib reverses P-gp-mediated MDR by directly inhibiting the efflux function of P-gp, indicating that cabozantinib may help to reverse P-gp-mediated MDR in HCC and other cancer chemotherapy.	cabozantinib	12-24	ATP binding cassette subfamily B member 1	Homo sapiens	98-102	
24621440-15	2015	CONCLUSION: Cabozantinib reverses P-gp-mediated MDR by directly inhibiting the efflux function of P-gp, indicating that cabozantinib may help to reverse P-gp-mediated MDR in HCC and other cancer chemotherapy.	cabozantinib	120-132	ATP binding cassette subfamily B member 1	Homo sapiens	34-38	
24621440-15	2015	CONCLUSION: Cabozantinib reverses P-gp-mediated MDR by directly inhibiting the efflux function of P-gp, indicating that cabozantinib may help to reverse P-gp-mediated MDR in HCC and other cancer chemotherapy.	cabozantinib	120-132	ATP binding cassette subfamily B member 1	Homo sapiens	98-102	
24621440-15	2015	CONCLUSION: Cabozantinib reverses P-gp-mediated MDR by directly inhibiting the efflux function of P-gp, indicating that cabozantinib may help to reverse P-gp-mediated MDR in HCC and other cancer chemotherapy.	cabozantinib	120-132	ATP binding cassette subfamily B member 1	Homo sapiens	98-102